Pyrophosphoric acid, tetrasodium-tin chloride salt
product is fixed in only 60% of the cases. Fixation is not
(PYROPHOSPATE)
stable in the case of threat or anguish syndrome.
Pharmacological category Pharmacokinetics
Pyrophosphate - 99mTc accumulates selectively in the
damaged myocardium and in imperfect osteogenic
Composition
zones of the skeleton. Uptake of this preparation is
TEXT: The Pyrophosphate - 99mTc complex binds
mainly to globulins and fibrinogen. Plasma concentration
Decahydrate sodium pyrophosphate 84.0 mg
reaches its maximum value 3-5 minutes after
administration, with a half-life of 9.8 h. A total of 60% of
the complex is excreted intact through the urine after 24
hours. The following table shows the dose absorbed in
humans following an injection of 99mTc-Sn-
Pharmacology
Radiation dose absorbed after an injection of 99mTc-Sn-
Pyrophosphate -Sn is a complex consisting of
Pyrophosphate and Sn2+. The 99mTc-Pirofosfato
complex is formed by adding a solution of 99mTcO -
vial containing the lyophilized, which exhibits marked
attraction for normal bony tissue when administered
intravenously. On the other hand, its distribution
throughout the body reflects metabolic changes around
lesions, a phenomenon which occurs before the
accumulation and re-absorption of calcium by the bone
and observable with a radiographic system. Therefore
this procedure can be used for the early diagnosis of
bone metastasis. The exact structure of the complex is
Indications
Following the endovenous administration of a solution
Used for In vivo labeling of circulating red blood cells
of Pyrophosphate –Sn, Sn2+ diffuses into the red blood
with 99mTc for visualizing the cavities of the heart using
cells circulating in the system. When Na99mTcO4 is
Gammagraphy and nuclear ventriculography;
injectedi n the system, 99mTc is reduced with the
visualization of the choroid plexus, diagnosis of occult
subsequent formation of a chelate with the beta chain
of the globulin molecule. The red blood is now labeled.
After 15 minutes, approximately 98% of the activity is
Contraindications
located in the red blood cells. After 18 hours, over 97%
of the red blood cells have been labeled. Under these
• Hypersensitivity to any of the components in the
conditions, it is possible to obtain images of the choroid
Tc-Sn-Pirofosfato accumulates in the mitochondria
of muscle cells in areas where acute myocardial • This preparation should not be administered to
infarction has occurred. During Gammagraphy of the
nursing mothers as sodium pertechnetate99 is passed
heart, pyrophosphate fixation intensity in septal infarcts
dating less than 8 days is practically proportional to the
Precautions
creatine-phosphokinase peak. After 8 days, fixation is
either weak or null. In the case of primary infarcts, the
CENTRO DE ISÓTOPOS: Ave. Monumental y Carretera La Rada, Km 3 ½ , Guanabacoa, Ciudad de la habana, Cuba. Telef.: (53) (7) 682 1836 y 682 9524; Pizarra:(53) (7) 682 9563 al 70 ext. 176 y 112 Fax: (53) (7) 866 9821; (53) (7) 682 7850 E-mail: comercial@centis.edu.cu PIROFOSFATO -Sn para marcaje con 99MTc
• This preparation should be administered only by
qualified personnel duly authorized to handle Dose radioisotopes.
• Administer to pregnant women only when strictly Intravenous administration of the entire solution to
necessary as it is not known if this patients weighing over 50kg. Administer half of the radiopharmaceutical can cause fetal damage or
solution to patients whose body weight is less or equal to
50 kg. After 20 minutes, inject a solution of 99mTcO -
Warnings Overdose
• Make sure that both the patient and clinical staff
working with radiopharmaceuticals receive as little
There are no reports regarding the symptoms due to an
overdose while using this product. Medial studies with
• This preparation is sterile and non-pyrogenic and radionuclides are conducted using very small
concentrations of the radiopharmaceutical which
• Do not use after 2 hours following reconstitution. consequently have no pharmacological effects. The only
possible effect resulting from an overdose would be the
• Dot not administer through a plastic catheter or additional radiation of the patient. The dose absorbed
from an injection of Pyrophosphate -99mTc is low and
• Labeling reactions with 99mTc must keep tin ions in
safe and consequently additional actions are not
their reduced state and consequently Sodium required in the event of an overdose. Pertechnetate 99mTc injections containing oxidants
Instructions for use Interactions with other medications
Pour 4 - 5 ml of, sterile non-pyrogenic injection water into
the vial with the lyophilized Pyrophosphate-Sn
Low labeling efficiency has been reported due to the
preparation. Eliminate the air in the needle as mush as
co-administration of: digoxin; metyldopa, nifedipine, possible. Shake the vial for 1 or 2 minutes until the quinidine, prazosin and iodine contrast media.
lyophilized has completely dissolved. The solution must
Adverse reactions
Administration of radiopharmaceuticals to patients will
inevitably generate a certain amount of radiation, The product is stored at 2- 80C. however somatic changes or genetic damage have
After reconstitution, the preparation must be stored at
been reported only during long term treatments room temperature in an armored lead casing. Although this risk may initially seem insignificant it must
be borne in mind whenever treating a patient with
Radiological safety measures
radiopharmaceuticals. The use of these preparations is
justified as long as the benefits outweigh the possible
The same measures normally used when handling open
risks posed by the use of radioactive material.
source diagnostic preparations, in keeping with the
Allergic reactions due to the use of radiopharmaceuticals in most cases exhibit several
clinical symptoms such as fever, flush, nauseas and a
variety of rashes such as urticaria and erythema. Other
types of allergic reactions associated with the endovenous administration of the radiopharmaceuticals Presentation:
such as pain or irritation at the administration site of the
CENTRO DE ISÓTOPOS: Ave. Monumental y Carretera La Rada, Km 3 ½ , Guanabacoa, Ciudad de la habana, Cuba. Telef.: (53) (7) 682 1836 y 682 9524; Pizarra:(53) (7) 682 9563 al 70 ext. 176 y 112 Fax: (53) (7) 866 9821; (53) (7) 682 7850 E-mail: comercial@centis.edu.cu PIROFOSFATO -Sn para marcaje con 99MTc
Registration No.: CENTRO DE ISÓTOPOS: Ave. Monumental y Carretera La Rada, Km 3 ½ , Guanabacoa, Ciudad de la habana, Cuba. Telef.: (53) (7) 682 1836 y 682 9524; Pizarra:(53) (7) 682 9563 al 70 ext. 176 y 112 Fax: (53) (7) 866 9821; (53) (7) 682 7850 E-mail: comercial@centis.edu.cu